Clinical trials: Illness, Chronic
Chronic Inducible Urticaria
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
- Trial name
- CALM-CIndU (NCT06050928)
- Testing
- Oral EP262
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Escient Pharmaceuticals, Inc
Hepatitis C, Chronic
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Based on previous experience with peginterferon alfa-2b/ribavirin in combination with boceprevir, the combination with peginterferon alfa- 2a/ribavirin and boceprevir is expected to be safe and well tolerated.
- Trial name
- NCT00845065
- Testing
- Boceprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 202 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD
Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
The mean objectives are to evaluate the impact of BDP/FF/G fixed combination on health-status and adherence
- Trial name
- NCT03963167
- Testing
- BDP/FF/G fixed combination
- Where
- Italy
- Volunteers
- 661 people
- Sponsor
- Chiesi Italia
Chronic Obstructive Pulmonary Disease, Lung Disease
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
The purpose of this research study is to evaluate the effect of AZD3199 on the electrical activity of the heart. The effect of AZD3199 will be compared to a licensed antibiotic (moxifloxacin).
- Trial name
- NCT01222442
- Testing
- AZD3199, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Select Relapsed/Refractory Lymphoid Malignancies
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies.
- Trial name
- VIJAY-1 (NCT06761586)
- Testing
- AUR104
- Where
- 5 sites in India
- Volunteers
- 9 people
- Sponsor
- Aurigene Discovery Technologies Limited
Chronic Lymphocytic Leukemia
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients…
- Trial name
- NCT00779883
- Testing
- ISF35
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memgen, LLC
Pulmonary Disease, Chronic Obstructive
ICS/LABA Adherence and COPD Exacerbation
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD…
- Trial name
- NCT02446041
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- AstraZeneca
Health, Health Adult Subjects
DBM-1152A Inhalation Solution in Chinese Healthy Subjects
This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A…
- Trial name
- NCT07447141
- Testing
- DBM-1152A Inhalation Solution
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Adult, Risk Factors
PUMA Implementation 2
COPD is underdiagnosed and spirometry is not widely available in primary care settings. This study explore the value of PUMA´s questionnaire in a case finding strategy to detect patients to perform spirometry in a real world…
- Conditions
- Adult, Risk Factors, Primary Care, COPD
- Trial name
- IPUMA2 (NCT03713931)
- Testing
- PUMA Score questionnaire
- Where
- 5 sites in Argentina
- Volunteers
- 1,000 people
- Sponsor
- Gustavo Zabert, MD
Anemia Associated With Chronic Kidney Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with…
- Trial name
- NCT03992066
- Testing
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Akebia Therapeutics
End Stage Renal Disease
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
VasQ is an external support implant for arteriovenous fistulas created for dialysis access. This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized…
- Trial name
- NCT06516653
- Testing
- VasQ, Arteriovenous fistula creation for dialysis vascular access
- Where
- 13 sites in United States
- Volunteers
- 300 people
- Sponsor
- Laminate Medical Technologies
Emphysema, Chronic Obstructive Pulmonary Disease
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
To establish and confirm the safety and clinical utility of BTVA applied unilaterally for lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.
- Trial name
- BTVA (NCT01102712)
- Testing
- BTVA System
- Where
- 10 sites in Australia, Austria and 2 more
- Volunteers
- 34 people
- Sponsor
- Uptake Medical Corp
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
COPD
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
This study will test two instruments to measure physical activity in COPD patients: A questionnaire and two small physical activity monitors .Patients will be randomized to either receive the telecoaching program in addition to…
- Trial name
- PROactive (NCT01992081)
- Testing
- Automated telehealth system, Usual care
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.
- Trial name
- NCT02339207
- Testing
- AL-335
- Where
- 3 sites in France, Georgia and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Pulmonary Disease, Chronic Obstructive
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and…
- Trial name
- NCT01899742
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 64 sites in United States, Argentina and 8 more
- Volunteers
- 497 people
- Sponsor
- GlaxoSmithKline
Anemia, Renal Insufficiency, Chronic
15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood.
- Trial name
- DIALOGUE 1 (NCT02021370)
- Testing
- BAY85-3934
- Where
- 56 sites in Australia, Bulgaria and 12 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Renal Insufficiency, Chronic
To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
The study investigates the pharmacokinetics (absorption, distribution, elimination) of molidustat after intake of a single 75 mg tablet in subjects with renal impairment requiring hemo- or peritoneal dialysis compared to age-and…
- Trial name
- NCT02312973
- Testing
- Molidustat(BAY85-3934)
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
The decrease in physical activity due to increasing dyspnoea that over time leads to a steadily worsening condition and increasing restriction of physical functioning is a key problem for COPD patients and affects even the early…
- Trial name
- NCT02173769
- Testing
- Spiriva® Respimat®, Striverdi® Respimat®
- Where
- 701 sites in Germany
- Volunteers
- 1,845 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
The purpose of this study is to assess the safety and tolerability of PUR0200. In addition, the study will look at the blood levels of different doses of PUR0200 and their affect on lung function in COPD patients.
- Trial name
- NCT01921712
- Testing
- PUR0200, Active comparator
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Pulmatrix Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.